Haleon (NYSE:HLN) Cut to “Hold” at Rothschild & Co Redburn

Haleon (NYSE:HLN) was downgraded by analysts at Rothschild & Co Redburn from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

HLN has been the subject of a number of other reports. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Argus raised Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Haleon Price Performance

Shares of NYSE:HLN opened at $9.09 on Tuesday. The company’s fifty day moving average price is $9.31 and its 200 day moving average price is $9.90. Haleon has a 12 month low of $8.65 and a 12 month high of $11.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The firm has a market capitalization of $40.20 billion, a P/E ratio of 23.30, a P/E/G ratio of 2.07 and a beta of 0.13.

Haleon (NYSE:HLN) last released its quarterly earnings data on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The company had revenue of $3.65 billion during the quarter. As a group, sell-side analysts predict that Haleon will post 0.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haleon

Hedge funds have recently modified their holdings of the stock. Parallel Advisors LLC grew its position in Haleon by 20.4% in the 1st quarter. Parallel Advisors LLC now owns 30,272 shares of the company’s stock valued at $303,000 after buying an additional 5,134 shares during the last quarter. Allen Capital Group LLC raised its position in Haleon by 14.5% during the 1st quarter. Allen Capital Group LLC now owns 13,628 shares of the company’s stock worth $136,000 after buying an additional 1,729 shares during the last quarter. Summitry LLC lifted its stake in shares of Haleon by 4.2% in the 1st quarter. Summitry LLC now owns 52,951 shares of the company’s stock worth $530,000 after acquiring an additional 2,136 shares during the period. Western Wealth Management LLC acquired a new stake in shares of Haleon in the 1st quarter worth $29,000. Finally, Bank of America Corp DE increased its stake in shares of Haleon by 17.0% during the first quarter. Bank of America Corp DE now owns 10,934,228 shares of the company’s stock worth $109,452,000 after acquiring an additional 1,586,230 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.